MorphoSys AG
MOR.DE
Deutsche Börse67.25
EUR
-0.45
- -
MorphoSys AG
MOR.DE
(Deutsche Börse)
Recent
price
67.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MorphoSys AG is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibody therapies primarily for oncology and inflammation. Founded in 1992 and headquartered in Planegg, Germany, the company specializes in fully human monoclonal antibodies using proprietary antibody, protein, and peptide technologies including the Human Combinatorial Antibody Library (HuCAL®), which enables rapid generation and optimization of therapeutic antibodies. MorphoSys's portfolio includes proprietary drug candidates and partnered programs across cancer, inflammatory and infectious diseases, with significant emphasis on treatments targeting blood cancers such as leukemia. Its main products and services encompass antibody-based therapeutics for oncology; proprietary technology platforms for antibody discovery and development; and collaborations with pharmaceutical and biotechnology companies for drug licensing and co-development. In the latest major corporate developments, MorphoSys was acquired by Novartis AG in 2024 for approximately €2.7 billion, integrating its oncology pipeline and antibody expertise into Novartis's broader pharmaceutical operations. Alongside this acquisition, MorphoSys entered into a strategic funding partnership with Royalty Pharma plc for over $2 billion to support expansion and accelerate the development, approval, and commercialization of breakthrough cancer therapies. Prior to this, the company completed the acquisition of Constellation Pharmaceuticals to broaden its therapeutic capabilities. MorphoSys also recently completed voluntary delisting from Nasdaq and the Frankfurt Stock Exchange as part of its integration with Novartis. These changes underscore a strategic shift toward enhanced in-house drug development and leveraging its proprietary antibody technologies within a larger global pharmaceutical framework. MorphoSys operates predominantly in Europe and the United States, with a focus on clinical development and commercialization of novel biopharmaceuticals for healthcare providers and patients in oncology and autoimmune disease markets. The company maintains a significant research footprint in Germany and the US, targeting cutting-edge biologics for unmet medical needs. It has established numerous partnerships with major pharmaceutical firms such as Bayer, Johnson & Johnson, and Roche to license technology platforms and co-develop drugs. MorphoSys’s business model combines proprietary drug development and extensive collaborative licensing agreements, leveraging its antibody technologies across therapeutic areas. Its proprietary pipeline, technology platforms, and partnerships position it as a key player in the biotechnology sector, focused on improving treatments for cancer and inflammatory diseases with novel biologics. Overall, MorphoSys AG stands as an established innovator in antibody drug discovery and development, headquartered in Planegg, Germany, with global operations concentrated in the biopharmaceutical markets of oncology and inflammation, currently operating as a wholly-owned subsidiary of Novartis AG after a strategic acquisition in 2024.